Publications

Racial Disparity in Delivering Definitive Therapy for Intermediate/High-risk Localized Prostate Cancer: The Impact of Facility Features and Socioeconomic Characteristics.

01st Aug 2018

Friedlander DF,Trinh QC, Krasnova A, Lipsitz SR, Sun M, Nguyen PL, Kibel AS, Choueire TK, Weissman JS, Menon M, Abdollah F

Prostate Cancer Therapy

Brigham and Women's Hospital, Division of Urological Surgery, Harvard Medical School, Boston, MA, USA. Brigham and Women's Hospital, Division of Urological Surgery, Harvard Medical School, Boston, MA, USA; Center for Surgery and Public Health, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. Electronic address: qtrinh@bwh.harvard.edu. Center for Surgery and Public Health, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. Department of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, MA, USA. Vattikuti Urology Institute, Henry Ford Health System, Detroit, MI, USA.

 From European Urology: Abstract BACKGROUND: The gap in prostate cancer (PCa) survival between Blacks and Whites has widened over the past decade. Investigators hypothesize that this disparity may be partially attributable to differences in rates of definitive therapy between races. OBJECTIVE: To examine facility level variation in the use of definitive therapy among Black and White men for localized PCa.

From European Urology:

Abstract

BACKGROUND:

The gap in prostate cancer (PCa) survival between Blacks and Whites has widened over the past decade. Investigators hypothesize that this disparity may be partially attributable to differences in rates of definitive therapy between races.

OBJECTIVE:

To examine facility level variation in the use of definitive therapy among Black and White men for localized PCa.

To access the complete Abstract, please use the "Read more" link below:

https://www.ncbi.nlm.nih.gov/pubmed/28778619

JOIN US

STAY UP-TO-DATE ON THE LATEST NEWS AND UPDATES AND HELP US BY SPREADING THE WORD.